{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:21Z","timestamp":1786980381060,"version":"build-2736575974"},"reference-count":10,"publisher":"University of Toronto Press Inc. (UTPress)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Liver Journal"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) imposes adverse health outcomes but may also cause psychosocial and quality-of-life (QOL) challenges. Hepatitis B surface antigen (HBsAg) loss, whether spontaneous or due to treatment (ie, a functional cure), is associated with improved clinical outcomes, but the impact of HBsAg clearance on patient-reported outcome measures (PROMs) is poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Two surveys (hepatitis B self-stigma and hepatitis B\u2013related QOL [HBQOL]) were administered to adults with a history of CHB with documented HBsAg clearance from six Canadian hepatology clinics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eighty-four participants were enrolled (median age: 60 years; 53.6% male). Nearly three quarters (72.6%) of patients reported never feeling self-stigma. HBQOL scores improved across all six domains (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt; 0.001 for each), with the largest relative gains in psychological well-being (60% reduction), transmission concerns (55%), and stigma (53%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>HBsAg loss was associated with significant improvements in patient-reported stigma and QOL. These findings highlight the importance of incorporating PROMs into hepatitis B virus clinical care to better capture treatment experiences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3138\/canlivj-2026-0029","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T20:55:37Z","timestamp":1784321737000},"page":"475-479","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life and self-reported stigma following hepatitis B surface antigen loss: A multi-site study by the Canadian Hepatitis B Network"],"prefix":"10.3138","volume":"9","author":[{"given":"Jordyn","family":"Vienneau","sequence":"first","affiliation":[{"name":"Cumming School of Medicine, Snyder Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hin Hin","family":"Ko","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Gastrointestinal Research Institute Foundation, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis L","family":"Cooper","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E","family":"Doucette","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkashab","sequence":"additional","affiliation":[{"name":"Toronto Liver Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Gastrointestinal Research Institute Foundation, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Tam","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Crotty","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, Snyder Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S","family":"Coffin","sequence":"additional","affiliation":[{"name":"Cumming School of Medicine, Snyder Institute, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1696","reference":[{"issue":"5","key":"e_1_3_10_2_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/v12050515","article-title":"The lived experience of chronic hepatitis B: a broader view of its impacts and why we need a cure","volume":"12","author":"Tu T","year":"2020","unstructured":"Tu T, Block JM, Wang S, Cohen C, Douglas MW. The lived experience of chronic hepatitis B: a broader view of its impacts and why we need a cure. Viruses. 2020;12(5):515. https:\/\/doi.org\/10.3390\/v12050515. Medline: 32392763","journal-title":"Viruses"},{"issue":"4","key":"e_1_3_10_3_2","doi-asserted-by":"crossref","first-page":"101312","DOI":"10.1016\/j.jhepr.2024.101312","article-title":"Quality of life in patients with HBV infection: a systematic review and meta-analysis","volume":"7","author":"Fu MX","year":"2025","unstructured":"Fu MX, Lambert G, Cook A, . Quality of life in patients with HBV infection: a systematic review and meta-analysis. JHEP Rep. 2025;7(4):101312. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101312. Medline: 40115166","journal-title":"JHEP Rep"},{"issue":"11","key":"e_1_3_10_4_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/liv.13168","article-title":"Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China","volume":"36","author":"Huang J","year":"2016","unstructured":"Huang J, Guan ML, Balch J, . Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int. 2016;36(11):1595\u2013603. https:\/\/doi.org\/10.1111\/liv.13168. Medline: 27206379","journal-title":"Liver Int"},{"issue":"3","key":"e_1_3_10_5_2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo YH","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, . Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635\u201346.e9. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.027. Medline: 30342034","journal-title":"Gastroenterology"},{"issue":"1","key":"e_1_3_10_6_2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/apt.16659","article-title":"Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B","volume":"55","author":"Vittal A","year":"2022","unstructured":"Vittal A, Sharma D, Hu A, . Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2022;55(1):8\u201325. https:\/\/doi.org\/10.1111\/apt.16659. Medline: 34850415","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"e_1_3_10_7_2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim GA","year":"2014","unstructured":"Kim GA, Lim YS, An J, . HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325\u201332. https:\/\/doi.org\/10.1136\/gutjnl-2013\u2013305517. Medline: 24162593","journal-title":"Gut"},{"issue":"12","key":"e_1_3_10_8_2","doi-asserted-by":"crossref","first-page":"e0854","DOI":"10.1097\/HC9.0000000000000854","article-title":"Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss","volume":"9","author":"Coffin C","year":"2025","unstructured":"Coffin C, Vienneau J, Cooper C, . Ultrasensitive detection of HBsAg and HBV genome analysis in a prospective cohort with chronic hepatitis B after HBV surface antigen loss. Hepatol Commun. 2025;9(12):e0854. https:\/\/doi.org\/10.1097\/HC9.0000000000000854. Medline: 41670594","journal-title":"Hepatol Commun"},{"issue":"1","key":"e_1_3_10_9_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.21692","article-title":"Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0","volume":"46","author":"Spiegel BMR","year":"2007","unstructured":"Spiegel BMR, Bolus R, Han S, . Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: the hepatitis B quality of life instrument, version 1.0. Hepatology. 2007;46(1):113\u201321. https:\/\/doi.org\/10.1002\/hep.21692. Medline: 17596882","journal-title":"Hepatology"},{"issue":"7","key":"e_1_3_10_10_2","first-page":"736452","article-title":"Health state utilities and quality of life in patients with hepatitis B","volume":"26","author":"Woo G","year":"2012","unstructured":"Woo G, Tomlinson G, Yim C, . Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol Hepatol. 2012;26(7):736452. https:\/\/doi.org\/10.1155\/2012\/736452","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_10_11_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jvh.13894","article-title":"Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life","volume":"31","author":"Natour RT","year":"2024","unstructured":"Natour RT, Midlej A, Mahajna E, Kopelman Y, Abo-Mouch S, Baker FA. Chronic hepatitis B beyond clinical burden: Psychosocial effects and impact on quality of life. J Viral Hepat. 2024;31(1):12\u201320. https:\/\/doi.org\/10.1111\/jvh.13894. Medline: 37920135","journal-title":"J Viral Hepat"}],"container-title":["Canadian Liver Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/utppublishing.com\/doi\/pdf\/10.3138\/canlivj-2026-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:42:15Z","timestamp":1786977735000},"score":1,"resource":{"primary":{"URL":"https:\/\/utppublishing.com\/doi\/10.3138\/canlivj-2026-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8,1]]}},"alternative-id":["10.3138\/canlivj-2026-0029"],"URL":"https:\/\/doi.org\/10.3138\/canlivj-2026-0029","relation":{},"ISSN":["2561-4444"],"issn-type":[{"value":"2561-4444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}